- Category: HCV Treatment
- Published on Wednesday, 27 May 2015 00:00
- Written by Liz Highleyman
Hepatitis C patients treated with AbbVie's Viekira Pak "3D" regimen saw improvements in liver function biomarkers, reported better quality of life, and had increased survival compared to untreated people, according to studies presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Other research showed that treatment can be cost-effective at all stages of liver disease.